Therapeutic potential of DMHCA for pulmonary arterial hypertension (PAH)

L. Taraseviciene-Stewart, M. Leberl, Z. Moumen, R. Kadam, U. Kompella, M. Zamora, A. Kratzer (Aurora, United States Of America)

Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Session: Pulmonary circulation: animal models and experimental treatments
Session type: Poster Discussion
Number: 492
Disease area: Pulmonary vascular diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Taraseviciene-Stewart, M. Leberl, Z. Moumen, R. Kadam, U. Kompella, M. Zamora, A. Kratzer (Aurora, United States Of America). Therapeutic potential of DMHCA for pulmonary arterial hypertension (PAH). Eur Respir J 2013; 42: Suppl. 57, 492

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013


Role of survivin in experimental models of pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016

Formation of typical vascular lesions in a new experimental model of pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013


Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015



Erythropoietin recapitulates hemodynamic features of hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016


Expression and function of aquaporin 1 in hypoxia-induced pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015

Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016

Intact serotonin signaling is not required for the development of severe angioproliferative pulmonary hypertension in rats
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014

Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016

Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013


Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014

Role of the TrkA receptor in experimental severe pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015

Epidemiological and Clinical aspects of pulmonary arterial hypertension (PAH)
Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Year: 2018

LATE-BREAKING ABSTRACT: Pneumonectomy combined with SU5416: a novel animal model of pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013


Role of microRNA 17/92 cluster and microRNA 21 in the pathogenesis of pulmonary hypertension – Novel therapeutic targets
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013

Pregnancy and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II
Year: 2013


Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015


Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015

Effect of POL6014, a protein epitope mimetic (PEM) neutrophil elastase inhibitor, in a model of monocrotaline (MCT)-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013

Repeated embolization and fibrinolysis inhibition induce chronic thromboembolic pulmonary hypertension in rabbits
Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers
Year: 2013